Moodley Jennifer R, Hoffman Margaret, Carrara Henri, Allan Bruce R, Cooper Diane D, Rosenberg Lynn, Denny Lynette E, Shapiro Samuel, Williamson Anna-Lise
School of Public Health and Family Medicine, Women's Health Research Unit, University of Cape Town, 7925, South Africa.
BMC Cancer. 2006 May 23;6:135. doi: 10.1186/1471-2407-6-135.
Cervical cancer and infection with human immunodeficiency virus (HIV) are both major public health problems in South Africa. The aim of this study was to determine the risk of cervical pre-cancer and cancer among HIV positive women in South Africa.
Data were derived from a case-control study that examined the association between hormonal contraceptives and invasive cervical cancer. The study was conducted in the Western Cape (South Africa), from January 1998 to December 2001. There were 486 women with invasive cervical cancer, 103 control women with atypical squamous cells of undetermined significance (ASCUS), 53 with low-grade squamous intraepithelial lesions (LSIL), 50 with high-grade squamous intraepithelial lesions (HSIL) and 1159 with normal cytology. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multiple logistic regression.
The adjusted odds ratios associated with HIV infection were: 4.4 [95% CI (2.3 - 8.4) for ASCUS, 7.4 (3.5 - 15.7) for LSIL, 5.8 (2.4 - 13.6) for HSIL and 1.17 (0.75 - 1.85) for invasive cervical cancer. HIV positive women were nearly 5 times more likely to have high-risk human papillomavirus infection (HR-HPV) present compared to HIV negative women [OR 4.6 (95 % CI 2.8 - 7.5)]. Women infected with both HIV and high-risk HPV had a more than 40 fold higher risk of SIL than women infected with neither of these viruses.
HIV positive women were at an increased risk of cervical pre-cancer, but did not demonstrate an excess risk of invasive cervical cancer. An interaction between HIV and HR-HPV infection was demonstrated. Our findings underscore the importance of developing locally relevant screening and management guidelines for HIV positive women in South Africa.
宫颈癌和人类免疫缺陷病毒(HIV)感染都是南非的主要公共卫生问题。本研究的目的是确定南非HIV阳性女性患宫颈上皮内瘤变和癌症的风险。
数据来自一项病例对照研究,该研究调查了激素避孕药与浸润性宫颈癌之间的关联。该研究于1998年1月至2001年12月在南非西开普省进行。有486名浸润性宫颈癌女性、103名意义不明确的非典型鳞状细胞(ASCUS)对照女性、53名低级别鳞状上皮内病变(LSIL)女性、50名高级别鳞状上皮内病变(HSIL)女性和1159名细胞学正常的女性。使用多因素逻辑回归计算比值比(OR)和95%置信区间(CI)。
与HIV感染相关的调整后比值比为:ASCUS为4.4 [95% CI(2.3 - 8.4)],LSIL为7.4(3.5 - 15.7),HSIL为5.8(2.4 - 13.6),浸润性宫颈癌为1.17(0.75 - 1.85)。与HIV阴性女性相比,HIV阳性女性感染高危人乳头瘤病毒(HR-HPV)的可能性几乎高5倍[OR 4.6(95% CI 2.8 - 7.5)]。同时感染HIV和高危HPV的女性患SIL的风险比未感染这两种病毒的女性高40多倍。
HIV阳性女性患宫颈上皮内瘤变的风险增加,但未显示出浸润性宫颈癌的额外风险。证实了HIV与HR-HPV感染之间存在相互作用。我们的研究结果强调了为南非HIV阳性女性制定当地相关筛查和管理指南的重要性。